{"id":2643,"date":"2011-01-03T17:24:52","date_gmt":"2011-01-03T22:24:52","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2643"},"modified":"2011-01-03T19:53:43","modified_gmt":"2011-01-04T00:53:43","slug":"illinois-start-up-licenses-anti-staph-infection-research","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2643","title":{"rendered":"Illinois Start Up Licenses Anti-Staph Infection Research"},"content":{"rendered":"<figure id=\"attachment_898\" aria-describedby=\"caption-attachment-898\" style=\"width: 200px\" class=\"wp-caption alignright\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-898\" title=\"MRSA_CDC\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC.jpg\" alt=\"MRSA bacteria (CDC)\" width=\"200\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC-150x150.jpg 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><figcaption id=\"caption-attachment-898\" class=\"wp-caption-text\">Scanning electron micrograph image of MRSA bacteria (Janice Haney Carr, Centers for Disease Control and Prevention)<\/figcaption><\/figure>\n<p>Start up company <a href=\"http:\/\/immuven.net\/index.html\">ImmuVen<\/a> in Champaign, Illinois agreed to <a href=\"http:\/\/otm.illinois.edu\/features\/2011-01-03\/illinois-innovation-change-how-scientists-treat-mr\">license new technology and processes<\/a> for treating methicillin-resistant Staphylococcus aureus (MRSA) from University of Illinois in Urbana-Champaign. ImmuVen was founded by the technology&#8217;s inventors, microbiologists <a href=\"http:\/\/mcb.illinois.edu\/faculty\/profile\/967\">David Kranz<\/a> of the University of Illinois Urbana-Champaign and <a href=\"http:\/\/www.bti.umn.edu\/faculty\/bioschlievert.html\">Patrick Schlievert<\/a> of the University of Minnesota in Minneapolis.<\/p>\n<p>MRSA is a type of staph bacteria that is resistant to certain antibiotics, and is still predominantly related to exposures to health care delivery. According to the U.S. <a href=\"http:\/\/www.cdc.gov\/mrsa\/index.html\">Centers for Disease Control and Prevention<\/a>, more than 94,000 people in the U.S. developed a serious MRSA infection in 2005. Some 18,650 persons died during a hospital stay related to these serious MRSA infections.<\/p>\n<p>ImmuVen&#8217;s technology engineers T cell receptor proteins for treatments where conventional drugs have so far not been unsuccessful. T cell receptors are found on the surface of T cells, a major type of white blood cells that fights disease. T cells resemble antibodies in that they can recognize foreign antigens.<\/p>\n<p>Unlike standard MRSA treatments, ImmuVen&#8217;s T cell receptor proteins target the toxins rather than destroying the invading bacteria. Once toxins are released into a person&#8217;s bloodstream, that person will remain sick even after the organism releasing the toxins is killed. To prevent the toxicity, ImmuVen engineered a T cell receptor protein that binds to and neutralizes the toxins.<\/p>\n<p>Related: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=834\">Drug Companies Urged to Conserve Antibiotics to Fight Resistance<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Start up company ImmuVen in Champaign, Illinois agreed to license new technology and processes for treating methicillin-resistant Staphylococcus aureus (MRSA) from University of Illinois in Urbana-Champaign. ImmuVen was founded by the technology&#8217;s inventors, microbiologists David Kranz of the University of Illinois Urbana-Champaign and Patrick Schlievert of the University of Minnesota in Minneapolis. MRSA is a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,15],"tags":[31,84,64,26],"class_list":["post-2643","post","type-post","status-publish","format-standard","hentry","category-i-p","category-products","tag-biomedical","tag-licensing","tag-life-sciences","tag-university"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2643"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2643\/revisions"}],"predecessor-version":[{"id":2647,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2643\/revisions\/2647"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}